The Nash pipeline is pharmacologically diverse, and some projects look like very long shots.
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
EQRX tears up plans to challenge US PD-(L)1 players on price, and switches focus to two non-discounted small molecules.
Immunogen and Uniqure are also set for Pdufa conclusions.
Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.